MAP2K1 and cancer: These results support the further investigation of delivery of MEK1 to macrophages as a form of cancer therapy while also developing better targeting of MEK1 inhibitors to specifically inhibit MEK1 in tumours while sparing MEK1 activity in immune cells such as macrophages.